PCKS9通过TLR4/NF-κB/COX-2途径调节单核-内皮细胞黏附性
DOI:
作者:
作者单位:

(1.贵州医科大学临床医学院,贵州省贵阳市550000;2.贵州医科大学附属医院心血管内科,贵州省贵阳市550000;3.贵州省人民医院神经电生理中心,贵州省贵阳市550000)

作者简介:

鲍海龙,硕士研究生,住院医师,研究方向为冠心病与血脂,E-mail为359077777@qq.com。通信作者李洁琪,博士,教授,硕士研究生导师,研究方向为冠心病与血脂,E-mail为1469052469@qq.com。

通讯作者:

基金项目:


PCKS9 regulates monocyte-endothelial cell adhesion via TLR4/NF-κB/COX-2 pathway
Author:
Affiliation:

1.Clinical Medical College of Guizhou Medical University;2.Department of Cardiology, Affiliated Hospital of Guizhou Medical University;3.Neurophysiology Center of People's Hospital of Guizhou, Guiyang, Guizhou 550000, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 探讨前蛋白转化酶枯草溶菌素9(PCSK9)是否通过人脐静脉内皮细胞(HUVECs)Toll样受体4(TLR4)/核因子κB(NF-κB)/环氧合酶2(COX-2)途径调节单核-内皮细胞黏附性。方法 氧化型低密度脂蛋白(ox-LDL)处理HUVECs,real-time PCR与Western blot法检测PCSK9、TLR4、NF-κB p65、COX-2 mRNA和蛋白表达;ox-LDL处理后,用人重组PCSK9蛋白孵育或PCSK9 siRNA转染HUVECs,检测TLR4、NF-κB p65、COX-2 mRNA和蛋白表达;ox-LDL处理后,用人重组PCSK9蛋白与TLR4抑制剂瑞沙托维(TAK-242)或NF-κB抑制剂吡咯烷二硫代氨基甲酸(PDTC)共同孵育HUVECs,检测NF-κB p65与COX-2的mRNA和蛋白表达;COX-2抑制剂(NS398)与人重组PCSK9蛋白先后处理HUVECs后,加入THP-1单核细胞检测单核-内皮细胞黏附性。结果 ox-LDL上调HUVECs的PCSK9、TLR4、NF-κB p65、COX-2 mRNA和蛋白表达(P均<0.05);人重组PCSK9蛋白在ox-LDL基础上上调TLR4、NF-κB p65、COX-2 mRNA和蛋白表达(P均<0.05);PCSK9 siRNA转染可抑制ox-LDL对TLR4、NF-κB p65、COX-2 mRNA和蛋白表达的上调作用(P均<0.05);TAK-242抑制人重组PCSK9蛋白对TLR4、NF-κB p65 mRNA和蛋白表达的上调作用(P均<0.05);PDTC抑制人重组PCSK9蛋白对NF-κB p65、COX-2 mRNA和蛋白表达的上调作用(P均<0.05);NS398可抑制人重组PCSK9蛋白的促单核-内皮细胞黏附作用(P均<0.05)。结论 PCSK9可通过TLR4/NF-κB/COX-2途径调节单核-内皮细胞黏附性。

    Abstract:

    Aim To investigate whether proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates monocyte-endothelial cell adhesion through Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB)/cyclooxygenase-2 (COX-2) pathway in human umbilical vein endothelial cells (HUVECs). Methods HUVECs were incubated with oxidized low density lipoprotein (ox-LDL), real-time PCR and Western blot assay for detection of PCSK9, TLR4, NF-κB, COX-2 mRNA and protein expression. After treatment with ox-LDL, recombinant PCSK9 protein was incubated or PCSK9 siRNA was transfected into HUVECs. Then the expression of TLR4, NF-κB p65, COX-2 mRNA and protein was detected. After treatment with ox-LDL, human recombinant PCSK9 protein was incubated with TLR4 inhibitor TAK-242 or NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) to detect mRNA and protein expression of NF-κB p65 and COX-2. After COX-2 inhibitor (NS398) and human recombinant PCSK9 protein were treated successively, THP-1 monocytes were added and monocyte-endothelial cell adhesion was detected. Results ox-LDL up-regulates the mRNA and protein expression of PCSK9, TLR4, NF-κB and COX-2 in HUVECs (all P<0.05). Human recombinant PCSK9 protein up-regulated TLR4, NF-κB, COX-2 mRNA and protein expression on ox-LDL basis (all P<0.05). PCSK9 siRNA transfection down-regulated the up-regulation of TLR4, NF-κB, COX-2 mRNA and protein expression by ox-LDL (all P<0.05). TAK-242 inhibits the up-regulation of TLR4 and NF-κB mRNA and protein expression by human recombinant PCSK9 protein (all P<0.05). PDTC inhibits the up-regulation of NF-κB and COX-2 mRNA and protein expression by human recombinant PCSK9 protein (all P<0.05). NS398 inhibits monocyte-endothelial cell adhesion induced by human recombinant PCSK9 protein (all P<0.05). Conclusion PCSK9 regulates monocyte-endothelial cell adhesion via TLR4/NF- κ B/COX-2 pathway.

    参考文献
    相似文献
    引证文献
引用本文

鲍海龙,廖付军,方俐,钟菲,刘稳,李洁琪. PCKS9通过TLR4/NF-κB/COX-2途径调节单核-内皮细胞黏附性[J].中国动脉硬化杂志,2019,27(5):395~400.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2018-11-02
  • 最后修改日期:2019-01-14
  • 录用日期:
  • 在线发布日期: 2019-04-08